De Angelis C et al. |
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. |
2013 May-Jun |
Tumori |
pmid:24158083
|
Poon KA et al. |
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. |
2013 |
Toxicol. Appl. Pharmacol. |
pmid:24035823
|
Wehrli W |
Ansamycins. Chemistry, biosynthesis and biological activity. |
1977 |
Top Curr Chem |
pmid:74108
|
Hull RN et al. |
Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. |
1977 |
Thromb. Res. |
pmid:18812
|
Liang Y et al. |
A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. |
2017 |
Theranostics |
pmid:28900511
|
Vankemmelbeke M and Durrant L |
Third-generation antibody drug conjugates for cancer therapy--a balancing act. |
2016 |
Ther Deliv |
pmid:26893243
|
Sieber SM et al. |
Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. |
1978 |
Teratology |
pmid:694777
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Diéras V and Bachelot T |
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. |
2014 |
Target Oncol |
pmid:23852665
|
Iwasaki S |
[Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands]. |
1993 |
Tanpakushitsu Kakusan Koso |
pmid:8210422
|